Research Topics
Species | A GaedigkSummaryAffiliation: Children's Mercy Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype predictionAndrea Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 62108, USA
Pharmacogenomics 11:43-53. 2010..Allelic variants of cytochrome P450 CYP2D6 (CYP2D6), such as gene deletion, duplication, multiplication and conversion, contribute to the wide range of CYP2D6 activity. Novel gene arrangements were discovered and characterized...
Variability of CYP2J2 expression in human fetal tissuesAndrea Gaedigk
Children s Mercy Hospital, Division of Clinical Pharmacology, 2401 Gillham Rd, Kansas City, MO 64108, USA
J Pharmacol Exp Ther 319:523-32. 2006..Due to premature termination codons, none encodes functional protein. The mechanisms leading to variable amounts of immunoreactive protein and distinct pre- and postnatal CYP2J2 protein patterns warrant further investigation...
CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein?Andrea Gaedigk
Division of Clinical Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital and Clinics, Kansas City, MO, USA
Biochem Biophys Res Commun 336:1241-50. 2005..14408G/G that causes a premature stop codon in any splice variants that contain the 57bp intron 6 insertion. Therefore, no evidence for functional CYP2D7 transcripts was observed in Asian, Caucasian or African American individuals...
The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangementsAndrea Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
Eur J Clin Pharmacol 64:465-75. 2008..This study aimed at characterising the CYP2D6 gene locus in Coloured subjects and predict their phenotype status...
UGT2B17 and SULT1A1 gene copy number variation (CNV) detection by LabChip microfluidic technologyAndrea Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital and Clinics, Kansas City, MO 64108, USA
Clin Chem Lab Med 48:627-33. 2010..Quantitative assays to assess gene copy number are therefore becoming an integral part of accurate genotype assessment and phenotype prediction...
CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer statusAndrea Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
Drug Metab Dispos 34:563-9. 2006..Given a combined frequency of between 0.5 and 3% in African Americans and Asians, genotyping for CYP2D6*36 should improve the accuracy of genotype-based phenotype prediction in these populations...
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotypeA Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
Clin Pharmacol Ther 83:234-42. 2008..The AS tool warrants further prospective evaluation for CYP2D6 substrates and in additional ethnic populations...
CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCRAndrea Gaedigk
Division of Pediatric Pharmacology and Medical Toxicology, The Children s Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
Pharmacogenomics 13:91-111. 2012..Different platforms exist for copy number variation (CNV) detection; however, there are no gold standards. Robust methods are required that address specific challenges to accurately determine gene CNVs in complex gene loci...
Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populationsAndrea Gaedigk
Division of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
Eur J Clin Pharmacol 66:859-64. 2010..We aimed to resolve the CYP2D6 31 no-calls, determine the allele haplotype, and corroborate that CYP2D6 31 is associated with a poor metabolizer phenotype...
Detection and characterization of the CYP2D6*9x2 gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-callsAndrea Gaedigk
Laboratori de Referència de Catalunya, El Prat de Llobregat, Barcelona, Spain
Pharmacogenomics 12:1617-22. 2011..The goal of the study was to resolve this issue by characterizing the CYP2D6 gene locus in these patients...
CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphismAndrea Gaedigk
Division of Developmental Pharmacology and Medical Toxicology, The Children's Mercy Hospital and Clinics, Kansas City, MO 64108, USA
Clin Chem 49:1008-11. 2003
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populationsA Gaedigk
Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital, Kansas City, Missouri 64108, USA
Pharmacogenetics 8:305-13. 1998..Affected individuals may not only exhibit resistance to quinone-based cancer therapy because of a decreased production of cytotoxic drug metabolites, but may also be more susceptible to toxicities associated with toxicants...
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency dataA Gaedigk
Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital, and University of Missouri Kansas City, 64108, USA
Pharmacogenetics 9:669-82. 1999..For all individuals, the correct phenotype has been predicted. Discordant phenotype assignment occurred in only two individuals which subsequently was attributed to CYP2D6 inhibition by concomitant drug therapy...
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populationsA Gaedigk
Division of Pediatric Clinical Pharmacology and Toxicology, The Children s Mercy Hospital and Clinics, Kansas City, MO 64108, USA
Can J Physiol Pharmacol 79:841-7. 2001..Therefore, these alleles may be extremely rare or absent, and unless other novel polymorphisms exist in this Inuit group one would not anticipate any CYP2C9 poor metabolizer subjects among this population...
Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication eventsA Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
Clin Pharmacol Ther 81:242-51. 2007..Accurate identification of gene duplication events is essential to avoid false-positive ultrarapid metabolism assignments and thus, overestimation of predicted activity and increased risk for unwanted adverse events...
Unique CYP2D6 activity distribution and genotype-phenotype discordance in black AmericansAndrea Gaedigk
Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospital and Clinics, Kansas City, MO 64108 USA
Clin Pharmacol Ther 72:76-89. 2002..Although CYP2D6 has been studied extensively in different population groups, relatively little is known for black Americans...
Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotypeA Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
Clin Pharmacol Ther 81:817-20. 2007..The rationale for this study was to resolve the discordance and to describe the novel non-functional allelic variant of CYP2D6 and its frequency in populations of different ethnic backgrounds...
Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African AmericansA Gaedigk
Division of Clinical Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, MO 64108, USA
Pharmacogenomics J 5:173-82. 2005..CYP2D6(*)45 and (*)46 have a combined frequency of 4% and can be identified by a common SNP. Carriers are predicted to exhibit an extensive or intermediate CYP2D6 phenotype...
Ontogeny of dextromethorphan O- and N-demethylation in the first year of lifeM J Blake
Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
Clin Pharmacol Ther 81:510-6. 2007..In contrast, DM N-demethylation developed significantly more slowly over the first year of life. Genotype and the temporal acquisition of drug biotransformation are critical determinants of a drug response in infants...
Genetic Heterogeneity in the rRNA Gene Locus of Trichophyton tonsuransAndrea Gaedigk
Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, Missouri 64108, USA
J Clin Microbiol 41:5478-87. 2003..tonsurans from other dermatophytes. Of the 92 isolates evaluated, this genotyping scheme distinguished 12 distinct strains, providing evidence of genetic heterogeneity in T. tonsurans...
Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactionsJ S Leeder
Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada
Pharmacogenetics 8:211-25. 1998....
Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescentsGregory L Kearns
Division of Pediatric Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
J Clin Pharmacol 48:1356-65. 2008..The pharmacokinetic profile of oral and intravenous pantoprazole was similar in children ages 2 to 16 years. The doses used here were safe and well tolerated in this population...
Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquineKenda A Marcucci
Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Toxicology, Children's Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA
Drug Metab Dispos 30:595-601. 2002..1. These data indicate that CYP2D6.17 exhibits reduced metabolic activity toward all three commonly used CYP2D6 substrates, although specific effects on substrate affinity and turnover demonstrate some substrate dependence...
Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotypeJ Steven Leeder
Section of Developmental Pharmacology and Experimental Therapeutics, Department of Pediatrics, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
J Clin Pharmacol 48:1041-51. 2008..Although further development is required, these studies suggest that the [(13)C]-DM breath test offers promise as a rapid, minimally invasive phenotyping assay for CYP2D6 activity...
Multilocus genotyping identifies infections by multiple strains of Trichophyton tonsuransSusan M Abdel-Rahman
Division of Pediatric Clinical Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
J Clin Microbiol 45:1949-53. 2007..This communication details mixed Trichophyton tonsurans infections and highlights the need to confirm the presence of multiple strains in a clinical single isolate by use of a multilocus approach...
Tracking Trichophyton tonsurans through a large urban child care center: defining infection prevalence and transmission patterns by molecular strain typingSusan M Abdel-Rahman
Department of Pediatric Clinical Pharmacology, Children s Mercy Hospitals and Clinics, 2401 Gillham Rd, Suite 0411, Kansas City, MO 64108, USA
Pediatrics 118:2365-73. 2006..This investigation was designed to gain insight into the natural course of T. tonsurans infection...
Identification of CYP2D6 impaired functional alleles in Mexican AmericansHuai Rong Luo
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Mail Stop 1018, Breidenthal Building, 3901 Rainbow Blvd, Kansas City, KS 66160 7417, USA
Eur J Clin Pharmacol 61:797-802. 2005..To extend the genotyping analysis of the CYP2D6 gene and further explain variability of CYP2D6 activity in Mexican Americans by genetic factors...
Variability of CYP3A7 expression in human fetal liverJ Steven Leeder
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
J Pharmacol Exp Ther 314:626-35. 2005..2-fold (8.07 +/- 2.87, range 2.41 to 14.9 nmol/min/mg). Observed variability in CYP3A7 activity was not related to CYP3A7*2, and alternative regulatory mechanisms require further investigation...
Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effectGregory L Kearns
Director, Pharmacogenetics Core Laboratory, Division of Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
Drug Metab Dispos 38:894-7. 2010..0001) and the apparent elimination rate constant (K(el); p = 0.0012); no significant genotype-phenotype relationships were observed for omeprazole...
Omeprazole disposition in children following single-dose administrationGregory L Kearns
Departments of Pediatrics and Pharmacology, University of Missouri, Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA
J Clin Pharmacol 43:840-8. 2003....
Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defectsAraba A Adjei
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Birth Defects Res A Clin Mol Teratol 82:155-65. 2008..The purpose of this study was to characterize the variability of APAP sulfation in a panel of human fetal livers and to identify the sulfotransferases (SULT) isoform(s) responsible for catalyzing that activity...
Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosisMary Jayne Kennedy
Division of Pediatric Clinical Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, Kansas City, MO, USA
Clin Pharmacol Ther 75:163-71. 2004..Altered biotransformation of drugs in this patient population is likely enzyme- and isoform-specific and thus is apparent for only selected compounds that are substrates for enzymes other than CYP1A2, NAT-2, XO, and CYP2D6...
CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6Y W Francis Lam
Department of Pharmacology, University of Texas Health Science Center at San Antonio, 78284 6220, USA
Pharmacotherapy 22:1001-6. 2002..To assess the correlation between plasma concentrations of four commonly administered selective serotonin reuptake inhibitors (SSRIs) and the magnitude of cytochrome P450 (CYP) 2D6 inhibition...
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed motherGideon Koren
Motherisk Program, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada
Lancet 368:704. 2006
Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjectsAndrea Gaedigk
Clin Pharmacol Ther 73:575-6. 2003
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail"Siwaporn Chainuvati
Department of Medicine, Bassett Healthcare, Cooperstown, NY 13326, USA
Clin Pharmacol Ther 74:437-47. 2003..The Cooperstown 5+1 cocktail may be used to simultaneously assess the activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT2, and XO...
Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizersJoseph D Ma
PharmD, Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326 1394, USA
J Clin Pharmacol 44:570-6. 2004..LSS using S-warfarin concentrations is an efficient and accurate technique to evaluate S-warfarin AUC(0- infinity ) when using warfarin as a CYP2C9 probe drug...
Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotypingMyong-Jin Kim
Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA
J Clin Pharmacol 44:966-73. 2004..5%, interquartile range = 14.8%-23.5%). Weight-based single doses of omeprazole for CYP2C19 phenotyping did not exhibit dose dependency. Therefore, a weight-based approach may improve the quantitation of omeprazole/metabolites...
Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjectsAndrea Gaedigk
Clin Pharmacol Ther 77:228-30; author reply 230-1. 2005
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktailTatiana Shelepova
Department of Medicine, Clinical Pharmacology Research Center, Bassett Healthcare, Cooperstown, New York, USA
J Clin Pharmacol 45:1413-21. 2005..This triphasic oral contraceptive may have a clinically significant effect on the activity of some drug-metabolizing enzymes...
Comments on Hoskins et al. [(2005) drug metab dispos 33:1564-1565]Andrea Gaedigk
Drug Metab Dispos 34:504-5; author reply 506. 2006
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarinMyong-Jin Kim
Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA
Eur J Clin Pharmacol 62:431-6. 2006..CONCLUSIONS: Cigarette smoking does not affect CYP2C9 activity as evaluated using S-warfarin as a CYP2C9 probe. Fluvastatin is a weak inhibitor of CYP2C9 activity in both smokers and non-smokers...
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertensionIssam Zineh
Department of Pharmacy Practice, University of Florida, Gainesville, FL 32610, USA
Clin Pharmacol Ther 76:536-44. 2004..We investigated whether metoprolol plasma concentrations, CYP2D6 polymorphisms, or genotype-derived phenotype was associated with adverse effects or efficacy in patients with hypertension...
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarkerMyong-Jin Kim
Clinical Pharmacology Research Center, Department of Medicine, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA
Clin Pharmacol Ther 72:192-9. 2002..A gene-dose effect was observed. In addition, variations in endogenous sex steroid concentrations throughout the menstrual cycle did not influence CYP2C19 activity...
Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorderRobert L Findling
Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, OH 44106 5080, USA
Neuropsychopharmacology 31:1274-85. 2006..Certain gastrointestinal and behavioral activation events (aggressive reaction and nervousness) were reported more frequently in the youngest age group...
Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeineParvaz Madadi
Can Fam Physician 53:33-5. 2007..Options to reduce this risk include discontinuing codeine after 2 to 3 days of use and being aware of symptoms of potential opioid toxicity in both mothers and newborns...
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 inductionMichael L Lim
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
J Acquir Immune Defic Syndr 36:1034-40. 2004..LPV/RTV may increase PHT clearance via CYP2C9 induction. Management should be individualized to each patient; dosage or medication adjustments may be necessary...
Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsJoseph D Ma
Clinical Pharmacology Research Center, The Research Institute, Inc, 150 New Scotland Ave, Albany, NY 12208, USA
Antimicrob Agents Chemother 50:1130-5. 2006..Maribavir was safe and well tolerated. Taste disturbance was the most frequently reported adverse event. These results will further guide evaluation of the drug interaction potential and clinical development of maribavir...
Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout miceKim S Sugamori
Department of Pharmacology, University of Toronto, Medical Sciences Building 1, King s College Circle, Toronto, Ontario M5S 1A8, Canada
Mol Pharmacol 64:170-9. 2003..This knockout mouse model should be helpful in delineating the role that variation in acetylating enzymes plays in mediating interindividual differences in susceptibility to arylamine-induced chemical toxicity and/or carcinogenesis...
